International Journal of Medical and Pharmaceutical Research
2024, Volume-5, Issue-3
Original Research Article
A Study On Oligohydramnios and Its Perinatal Outcome
Published
June 8, 2024
Abstract

Background : Oligohydramnios is one of the major causes of perinatal morbidity and mortality. The sonographic diagnosis of oligohydramnios is usually based on an AFI≤5
cm or on a single deepest pocket of amniotic fluid≤2 cm.Our study was aimed to study the perinatal outcome in oligohydramnios. Aim and objective were to study maternal
outcome in the form of mode of delivery, and to assess neonatal complications in terms of APGAR score at birth, NICU admission rates, meconium stained liquor in oligohydramnios. Methods: This prospective study was done among 90 patients with gestational age from 28 - 42wks with Oligohydramnios AFI<5cms with intact membranes were analysed for perinatal outcomes admitted at department of obstetrics and Gynaecology in maharajah’s institute of medical sciences, vizianagaram during June 2022 to January 2024. Results: Mean maternal age is 26.1 years. Incidence of oligohydramnios was more in primipara (61.1%) in our study. Most AFI was in the range of 4-5 cm in53.3%. Operative delivery (63%)is more common with most common cause is fetal distress(23.3%).Most of them have clear liquor(60%) and mostly delivered at early term (43.3%).Most of them are born with birth weight of 2.5k kg to 2.9 kg (38.8%) and with APGAR >7 (83%) in most cases. Most common cause of NICU admission is
meconium aspiration syndrome (8.88%). Conclusion: AFI is an important and convenient screening test for prediction of perinatal outcome. In presence of oligohydramnios, the risk of fetal distress, operative delivery, low Apgar score, low birth weight, perinatal morbidity and mortality are more. Hence early detection of oligohydramnios, associated antenatal risk factors and timely management can improve the maternal and fetal outcome.

Recommended Articles
Loading Image...
Volume-5, Issue-3
Citations
2577 Views
373 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved